An active investing strategy involves searching for breakout stocks in a specific price range. When choosing breakout stocks, consider selling if the price falls below the lower band and holding for gains if it exceeds the upper band. To that end, Barclays PLC (BCS) , NatWest Group plc (NWG) , and Aris Mining Corporation (ARMN) have been selected as the breakout stocks for today. Zeroing in on Breakout Stocks To pick a breakout stock, calculate support and resistance levels. A support level is the lower bou ...

Shares of Carnival Corporation & plc CCL are trading lower Friday. This is despite analyst predictions of strong summer bookings.That’s why it’s Benzinga’s Stock of the Day. It looks like the shares may find support and reverse and move higher.The chart of Carnival illustrates two important market principles.The first is that price levels that had been support can turn into resistance levels. In December the $23.30 level was support. In May it became a resistance level.Support can turn into resistance becau ...

Core Insights - Purple Biotech Ltd. presented final Phase 2 data for CM24 at the AACR Annual Meeting 2025, showing significant efficacy in biomarker subgroup analyses, which supports the patient selection strategy for the upcoming Phase 2b study planned for the second half of 2025 [4][6] - The company is advancing its pipeline with NT219, which is on track for a Phase 2 study in head and neck cancer, and the CAPTN-3 tri-specific platform is moving towards first-in-human clinical trials [2][3] Clinical Developments - CM24 demonstrated a 78% reduction in risk of death and an 81% reduction in risk of progression or death in specific biomarker subgroups [6] - NT219 will be evaluated in a Phase 2 study in combination with pembrolizumab or cetuximab for recurrent/metastatic squamous cell carcinoma of the head and neck [5][7] - New data on NT219 presented at AACR highlighted its ability to overcome immune evasion mechanisms in head and neck cancer [8] Financial Performance - Research and Development Expenses decreased by 76.5% to $0.8 million for the three months ended March 31, 2025, compared to $3.4 million in the same period of 2024 [11] - General and Administrative Expenses also decreased to $0.6 million from $1 million year-over-year [12] - The net loss for the period was $0.5 million, significantly reduced from $3.8 million in the same period of 2024, reflecting a decrease in operating expenses [15] Cash Position - As of March 31, 2025, the company had cash and cash equivalents of $6.7 million, providing a cash runway into mid-2026 [15] - The company sold approximately 63 thousand ADSs at an average price of $3.5 per ADS, generating net proceeds of approximately $166 thousand [16] Intellectual Property - A new U.S. patent for NT219 enhances global IP protection for its use in combination with EGFR antibodies, positioning the company well for future commercialization [10]

FRANKLIN LAKES, N.J., May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients.Key Takeaways: The Lancet Oncology (May 2025): Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospecti ...

Trading in shares of Microsoft Corporation MSFT is quiet Tuesday. It is consolidating after its recent historic move higher. The stock has gained more than 30% since the April lows.Microsoft is the biggest company in the market, and continued bullish action here could pull the broader market to new all-time highs. That’s why Benzinga has made it our Stock of the Day. Many traders and investors are still cautious about the market. This is despite the fact that the rally that began in early April has been his ...

Uber (UBER) FY Conference May 15, 2025 09:20 AM ET Speaker0 Alright. We're going to go ahead and get started. I'm Doug Anmuth, JPMorgan's Internet analyst. We're very pleased to have with us Uber's CEO, Daragh Hazrashahi. Uber's mission is to create opportunity through movement. Uber is a global leader in two secular growth industries, ride sharing and food delivery. Last year, the company generated $163,000,000,000 in gross bookings along with nearly $7,000,000,000 of free cash flow. Dara has been CEO of U ...

Iterum Therapeutics (ITRM) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs & SecretaryCorey Fishman - CEOJudith Matthews - Chief Financial OfficerMatthew Keller - Equity Research Associate Operator Hello, everyone, and thank you for joining the Ichorum Therapeutics plc First Quarter twenty twenty five Earnings and Business Update Call. My name is Lucy, and I'll be coordinating your call today. I will now hand over to your host, Loui ...

Shares Lyft, Inc. LYFT continue to move higher Monday. The company reported better than expected earnings. CEO David Risher said the quarter was the company's 16th consecutive one of double-digit year over year gross bookings growth.If the shares reach the $18.50 level, there is a good chance the move higher pauses or ends. There tends to be resistance at prices that had previously been resistance or a peak, and as you can see on the chart below, $18.50 was resistance in November. This is why our technical ...

榆林市农业技术服务中心定期发布榆林市土壤墒情简报，指导春播工作。该中心建议，当前榆林大 部分地区温度适宜，应抓住有利天气加快播种马铃薯、玉米，确保春播顺利开展。墒情偏差地区应加强 人工保墒增墒，应用地膜覆盖、膜下滴灌、水肥一体化等农田节水技术。有条件的地区和干旱较重地区 应加强农田灌溉，为后面大面积播种提供良好的墒情条件。 作为榆林的重要水源地之一，王圪堵水库在抗旱保供中发挥着重要作用。水库总库容3.89亿立方 米，年均向无定河下游抗旱补水超1亿立方米，并为榆林中心城区、榆横工业区、绥德、米脂及沿线多 个乡镇供水，覆盖近200万人口。近期，该水库不断增加输水量，通过东、南、西3条输水线路，最大限 度满足沿线农业灌溉和居民用水需求。 "目前，我们根据下游灌溉需水量，把下泄流量从3.8立方米每秒提升到7.67立方米每秒。今后，我 们将根据下游旱情发展情况逐步加大下泄流量，保证下游20万亩农田的灌溉用水。"榆林市水务集团王 圪堵水库有限责任公司总经理助理高耀东说。 入春以来，榆林有效降雨偏少，出现春旱天气。为确保春季农业生产，榆林市组织农业农村局、水 利局、供电公司等部门和单位成立12支市级春播入种和抗旱保粮技术指 ...

Core Viewpoint - BioVie Inc. is advancing its clinical-stage drug candidate bezisterim (NE3107) for the treatment of early Parkinson's disease, with a Phase 2 clinical trial named SUNRISE-PD set to present findings at the IAPRD 2025 conference in New York City [1][2]. Company Overview - BioVie Inc. (NASDAQ: BIVI) focuses on developing innovative drug therapies for neurological and neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and long COVID, as well as advanced liver disease [13]. - The company's lead candidate, bezisterim, is designed to modulate inflammation and enhance insulin sensitivity without immunosuppressive effects, potentially addressing multiple disease indications [8][13]. Clinical Trial Details - The SUNRISE-PD trial is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study lasting 20 weeks, evaluating bezisterim's safety and efficacy in patients with early Parkinson's disease [3][4]. - Patients can participate either from home or at clinical sites, with remote supervision by neurologists during assessments [4]. Parkinson's Disease Context - Parkinson's disease is characterized by the loss of dopamine-producing neurons, leading to motor and non-motor symptoms that significantly impact patients' quality of life [5]. - Traditional treatments like levodopa have limitations, including long-term complications such as motor fluctuations and dyskinesia [6]. Mechanism of Action - Bezisterim targets chronic inflammation and insulin resistance, which are linked to the progression of Parkinson's disease, by modulating neuroinflammation and metabolic dysfunctions [7][8]. Expected Outcomes - Topline data from the SUNRISE-PD trial is anticipated in late 2025 or early 2026, with previous studies indicating bezisterim's potential to improve motor control and reduce adverse events when combined with levodopa [9][10].